Medication info
Escar Tablet 5/40 mg

Escar Tablet 5/40 mg

Prescription medicationTabletOral
Ingredient · strength
Amlodipine Besylate›6.94mg / 1 tabletOlmesartan Medoxomil›40mg / 1 tablet
Manufacturer / importer
Samik Pharmaceutical Co., Ltd.
Appearance
Pale yellow round film-coated tablets
Packaging
28 tablets / PTP [(14 tablets/PTP x 2)]
Approval status
Active

MFDS item code 201902222 · Approved 2019.04.11 · Insurance code 644004140

Summary

Main use
Treatment of essential hypertension not adequately controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Administer 1 tablet of this drug once daily with water, with or without food. It is recommended to take it at the same time each day (e.g., in the morning), if possible. Before administering this drug, it is recommended that the dose of the individual component (amlodipine or olmesartan medoxomil) be adjusted; however, if blood pressure is not controlled with monotherapy with an individual component, switching directly to this drug may be considered. The maximum dose of this drug is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This drug has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild and moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and administration of this drug is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients taking diuretics, especially those with renal impairment), it is recommended to initiate treatment at a low dose with close monitoring of their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild and moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. Do not administer this drug to patients with severe hepatic impairment. (See section 2, Patients who should not receive this drug, under Precautions for Use.) ∘Older adults: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in older adults.
Child dose
The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Ingredients

Manufacturer
Samik Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not adequately controlled with monotherapy

  • Essential hypertension
View approved original text

This medication effectively controls blood pressure using either amlodipine or olmesartan medoxomil as monotherapy for patients with essential hypertension. These drugs help treat hypertension, stabilize blood pressure, and prevent complications. This medication is used when blood pressure does not sufficiently lower with monotherapy. Therefore, it plays a critical role in managing essential hypertension, improving blood pressure control with consistent usage.

How to take

Adult dose

Administer 1 tablet of this drug once daily with water, with or without food. It is recommended to take it at the same time each day (e.g., in the morning), if possible. Before administering this drug, it is recommended that the dose of the individual component (amlodipine or olmesartan medoxomil) be adjusted; however, if blood pressure is not controlled with monotherapy with an individual component, switching directly to this drug may be considered. The maximum dose of this drug is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This drug has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild and moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and administration of this drug is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients taking diuretics, especially those with renal impairment), it is recommended to initiate treatment at a low dose with close monitoring of their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild and moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. Do not administer this drug to patients with severe hepatic impairment. (See section 2, Patients who should not receive this drug, under Precautions for Use.) ∘Older adults: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in older adults.

Child dose

The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Precautions

This medication can cause severe harm or death to the fetus and newborn when administered to pregnant women in the second and third trimesters, so it must be immediately discontinued if pregnancy is confirmed. Patients who are allergic to this medication's active ingredients or related drugs, pregnant or nursing women, those with severe liver function impairment, patients with severe aortic stenosis, patients with biliary obstruction, patients undergoing renal dialysis, patients in shock, certain diabetic patients, and patients with severe renal impairment should not be administered this medication. In hypotensive patients with insufficient fluid or salt levels, initial administration may induce symptoms of hypotension, so monitoring their condition closely is essential; if hypotension occurs, the patient should be laid down and normal saline may be administered as needed. This medication works by dilating blood vessels to lower blood pressure, thus it should be administered cautiously in patients with severe aortic stenosis, obstructive coronary artery disease, or congestive heart failure. Patients with impaired renal function may experience further deterioration of their renal condition with this medication, necessitating regular monitoring of kidney function. Those with liver function impairment should also exercise caution when taking this medication. During treatment, side effects such as dizziness, headache, hypotension, edema, dyspepsia, skin rash, and others may occur, and patients should consult healthcare professionals if any unusual symptoms arise. It is recommended that women who are pregnant or planning to become pregnant switch to safer alternative treatments confirmed for their safety, and this medication should be discontinued as soon as pregnancy is confirmed. Nursing mothers should be aware that this medication may pass into breast milk and can cause adverse reactions in infants; thus, nursing should be stopped or the medication should be discontinued during breastfeeding. Safety and efficacy have not been established for pediatric patients under 18 years of age, hence use in this group is not recommended. Elderly patients may have reduced renal and liver function, thus starting at a lower dosage and closely monitoring their condition is necessary. In cases of overdose, hypotension and cardiac arrhythmias may occur; hence, blood pressure and cardiac function must be carefully monitored, and immediate treatment must be initiated if needed. Taking this medication with grapefruit juice may enhance its blood pressure-lowering effects, therefore, it is advisable to avoid grapefruit juice consumption. There may be interactions when combined with other medications, so it is crucial to inform healthcare professionals of any medications currently being taken. This medication should be kept out of reach of children and stored in a cool, dry place away from direct sunlight.

Side effects

  • Drug hypersensitivity
  • hyperkalemia
  • decreased libido
  • dizziness
  • headache
  • orthostatic hypotension
  • drowsiness
  • sensory disturbances
  • decreased sensation
  • syncope
Show 84 more
  • vertigo
  • palpitations
  • rapid pulse
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • cough
  • nausea
  • vomiting
  • dyspepsia
  • diarrhea
  • constipation
  • dry mouth
  • upper abdominal pain
  • rash
  • urticaria
  • muscle tension
  • limb pain
  • lower back pain
  • frequent urination
  • erectile dysfunction
  • peripheral edema
  • edema
  • dependent edema
  • fatigue
  • weakness
  • facial edema
  • decreased serum potassium
  • increased serum creatinine
  • increased serum uric acid
  • increased gamma-glutamyl transferase
  • decreased hemoglobin and hematocrit
  • cholelithiasis
  • female breast neoplasm
  • deterioration of cerebral infarction
  • gum bleeding
  • orthostatic dizziness
  • chest pain
  • cold
  • increased CRP
  • fever
  • hemoptysis
  • excessive sneezing
  • runny nose
  • laryngitis
  • arthritis
  • flank pain
  • generalized pain
  • hypoglycemia
  • weight loss
  • heartburn
  • gastroenteritis
  • shingles
  • double vision
  • weakness
  • vascular edema
  • chronic malabsorption syndrome
  • intestinal vascular edema
  • rhabdomyolysis
  • acute renal failure
  • hair loss
  • itching
  • autoimmune hepatitis
  • elevated serum creatinine
  • hyperkalemia
  • flushing
  • fatigue
  • edema
  • palpitations
  • dizziness
  • headache
  • drowsiness
  • abdominal pain
  • nausea
  • gynecomastia
  • jaundice
  • elevated liver enzymes
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • hypotension
  • tachycardia
  • bradycardia
  • non-cardiogenic pulmonary edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it must be stored in a tightly sealed container. Additionally, it is important to maintain the medication's effectiveness by storing it at a temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Pale yellow round film-coated tablets

Package unit

28 tablets / PTP [(14 tablets/PTP x 2)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.